Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.385 USD | +6.54% | +3.73% | +12.10% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.10% | 272M | |
-1.15% | 103B | |
+8.60% | 101B | |
+4.40% | 23.07B | |
-12.36% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.28% | 16.94B | |
+6.75% | 14.07B | |
+38.86% | 12.35B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- HC Wainwright Adjusts Price Target on Akebia Therapeutics to $2 From $1.25, Maintains Neutral Rating